Treatment selection for lung cancer patients using mass spectrum of blood-based sample
US9211314B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2014 |
| Grant date | Dec 15, 2015 |
| Priority date | — |
| Expiry date | Aug 15, 2034 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH01J49/26
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A test for predicting whether a non-small-cell lung cancer patient is more likely to benefit from an EGFR-I as compared to chemotherapy uses a computer-implemented classifier operating on a mass spectrum of a blood-based sample obtained from the patient. The classifier makes use of a training set which includes mass spectral data from blood-based samples of other cancer patients who are members of a class of patients predicted to have overall survival benefit on EGFRI-Is, e.g., those patients testing VS Good under the test described in U.S. Pat. No. 7,736,905. This class-labeled group is further subdivided into two subsets, i.e., those patients which exhibited early (class label “early”) and late (class label “late”) progression of disease after administration of the EGFR-I in treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.